NewLink Genetics (NASDAQ: NLNK) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.
Earnings & Valuation
This table compares NewLink Genetics and Editas Medicine’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NewLink Genetics||$28.71 million||9.38||-$71.95 million||($2.35)||-3.09|
|Editas Medicine||$13.73 million||113.19||-$120.32 million||($2.98)||-11.12|
This is a breakdown of recent ratings and recommmendations for NewLink Genetics and Editas Medicine, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NewLink Genetics currently has a consensus target price of $23.67, suggesting a potential upside of 226.44%. Editas Medicine has a consensus target price of $45.60, suggesting a potential upside of 37.56%. Given NewLink Genetics’ stronger consensus rating and higher probable upside, analysts plainly believe NewLink Genetics is more favorable than Editas Medicine.
Insider and Institutional Ownership
65.1% of NewLink Genetics shares are held by institutional investors. Comparatively, 64.5% of Editas Medicine shares are held by institutional investors. 13.7% of NewLink Genetics shares are held by company insiders. Comparatively, 19.4% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
NewLink Genetics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 3.68, meaning that its share price is 268% more volatile than the S&P 500.
This table compares NewLink Genetics and Editas Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
NewLink Genetics beats Editas Medicine on 10 of the 14 factors compared between the two stocks.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
About Editas Medicine
Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.